West Nile vaccine
AssigneeWyeth
InventorHsien-Jue Chu
Life of this patent
Estimating the term…
Abstract
The present invention provides a safe and effective vaccine composition against West Nile virus disease. An immunogenically active component of West Nile virus or plasmid DNA, an adjuvant such as a metabolizable oil, and a pharmacologically acceptable carrier are formulated into an immunizing vaccine. The invention also provides a method for the prevention or amelioration of West Nile disease, such as encephalitis, in equidae by administering the vaccine composition herein set forth.
Claims41
A safened vaccine composition which comprises:
- an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof;
- an immunogenically stimulating amount of a metabolizable oil;
- and a pharmacologically acceptable carrier.
A method for the prevention or amelioration of West Nile encephalitis in equidae which comprises administering to said equidae a safened vaccine composition which comprises an effective immunizing amount of an immunogenically active component selected from the group consisting of an inactivated whole or subunit West Nile virus, an antigen derived from said virus, DNA derived from said virus, and a mixture thereof;
- an immunogenically stimulating amount of a metabolizable oil;
- and a pharmacologically acceptable carrier.
A vaccine composition, comprising:
- a) at least about 1×104 TCID50 and up to about 1×109 TCID50 per unit dose of inactivated West Nile virus;
- and
- b) about 4% to 10% vol/vol of a metabolizable oil adjuvant comprising about 1 to 3% polyoxyethylene-polyoxypropylene block copolymer, about 2 to 6% of squalane and about 0.1 to 0.5% of polyoxyethylene sorbitan monooleate.
A safened and effective West Nile virus vaccine for equidae, comprising:
- a) at least about 1×106 TCID50 to about 1×108 TCID50 per unit dose of killed or inactivated West Nile virus, and
- b) at least about 1% vol/vol of an adjuvant comprising at least one metabolizable oil and at least one wetting or dispersing agent.
A vaccine regimen for horses or other equidae, comprising two dosage units of killed or inactivated West Nile virus, wherein each said dosage unit comprises about 0.5 to 5 milliliters of a composition containing at least about 5×107 TCID50 of said virus and about 1 to 10% vol/vol of an adjuvant, said adjuvant comprising at least one metabolizable oil and at least two nonionic surfactants, and further wherein said dosage unit comprises a pharmacologically acceptable carrier.
A West Nile virus vaccine composition comprising West Nile plasmid DNA in an amount of about 50 to 3,000 micrograms per dose.
Dependencies are inferred from the claim text.